ARCT
Price
$13.33
Change
-$1.08 (-7.49%)
Updated
Jun 27 closing price
Capitalization
361.25M
43 days until earnings call
NVAX
Price
$6.37
Change
-$0.13 (-2.00%)
Updated
Jun 27 closing price
Capitalization
1.03B
38 days until earnings call
Interact to see
Advertisement

ARCT vs NVAX

Header iconARCT vs NVAX Comparison
Open Charts ARCT vs NVAXBanner chart's image
Arcturus Therapeutics Holdings
Price$13.33
Change-$1.08 (-7.49%)
Volume$1.2M
Capitalization361.25M
Novavax
Price$6.37
Change-$0.13 (-2.00%)
Volume$3.8M
Capitalization1.03B
ARCT vs NVAX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. NVAX commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and NVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ARCT: $13.33 vs. NVAX: $6.38)
Brand notoriety: ARCT: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 266% vs. NVAX: 39%
Market capitalization -- ARCT: $361.25M vs. NVAX: $1.03B
ARCT [@Biotechnology] is valued at $361.25M. NVAX’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while NVAX’s TA Score has 2 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 3 bearish.
  • NVAX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than NVAX.

Price Growth

ARCT (@Biotechnology) experienced а +8.46% price change this week, while NVAX (@Biotechnology) price change was -0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.03B) has a higher market cap than ARCT($361M). NVAX (-20.709) and ARCT (-21.450) have similar YTD gains . NVAX has higher annual earnings (EBITDA): 555M vs. ARCT (-63.92M). NVAX has more cash in the bank: 731M vs. ARCT (217M). ARCT has less debt than NVAX: ARCT (42.7M) vs NVAX (229M). NVAX has higher revenues than ARCT: NVAX (1.22B) vs ARCT (131M).
ARCTNVAXARCT / NVAX
Capitalization361M1.03B35%
EBITDA-63.92M555M-12%
Gain YTD-21.450-20.709104%
P/E RatioN/A2.32-
Revenue131M1.22B11%
Total Cash217M731M30%
Total Debt42.7M229M19%
FUNDAMENTALS RATINGS
ARCT vs NVAX: Fundamental Ratings
ARCT
NVAX
OUTLOOK RATING
1..100
2057
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
5885
P/E GROWTH RATING
1..100
10054
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVAX (87) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than NVAX’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NVAX’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NVAX’s over the last 12 months.

ARCT's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as NVAX (85) in the Biotechnology industry. This means that ARCT’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that NVAX’s stock grew somewhat faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTNVAX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
N/A
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NRAAX51.020.34
+0.67%
Neuberger Berman Sustainable Equity A
FVRMX24.720.12
+0.49%
Franklin Mutual Small-Mid Cap Val Adv
TGPEX11.010.04
+0.36%
T. Rowe Price Global Impact Equity Inv
NWAOX35.290.08
+0.23%
Nationwide BNY Mellon Dyn US Eq Inc I.S
MTRRX19.680.02
+0.10%
MFS Total Return R2

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-7.49%
TRDA - ARCT
53%
Loosely correlated
-1.57%
RGNX - ARCT
52%
Loosely correlated
-4.11%
ABCL - ARCT
51%
Loosely correlated
-3.48%
MRNA - ARCT
50%
Loosely correlated
-1.38%
RXRX - ARCT
49%
Loosely correlated
-6.85%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.92%
MRNA - NVAX
45%
Loosely correlated
-1.38%
ARCT - NVAX
43%
Loosely correlated
-7.49%
BNTX - NVAX
42%
Loosely correlated
+0.55%
CRSP - NVAX
40%
Loosely correlated
N/A
XNCR - NVAX
39%
Loosely correlated
-3.10%
More